Aisling Capital Management LP 13F Holdings · Q2 2026
Aisling Capital Management LP reported 14 securities worth $471.62M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: BBIO (72.48%), GLUE (7.98%), SNDX (6.10%). Among its top 25 positions this quarter: 1 new, 1 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | BBIO | BRIDGEBIO PHARMA INC | $341.8M | 72.48% | 4.6M | Trimmed |
| 2 | GLUE | MONTE ROSA THERAPEUTICS INC | $37.6M | 7.98% | 1.6M | Hold |
| 3 | SNDX | SYNDAX PHARMACEUTICALS INC | $28.8M | 6.10% | 1.3M | Hold |
| 4 | CMPS | COMPASS PATHWAYS PLC | $20.3M | 4.30% | 1.4M | Hold |
| 5 | BCAX | BICARA THERAPEUTICS INC | $16.9M | 3.58% | 568,919 | Hold |
| 6 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $7.8M | 1.64% | 1.0M | Hold |
| 7 | SRRK | SCHOLAR ROCK HLDG CORP | $4.2M | 0.90% | 77,031 | Hold |
| 8 | URGN | UROGEN PHARMA LTD | $4.0M | 0.84% | 108,000 | Hold |
| 9 | BMEA | BIOMEA FUSION INC | $3.0M | 0.64% | 2.0M | Hold |
| 10 | ACRS | ACLARIS THERAPEUTICS INC | $2.3M | 0.49% | 434,455 | Hold |
| 11 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $2.1M | 0.46% | 325,000 | Hold |
| 12 | VTVT | VTV THERAPEUTICS INC | $1.9M | 0.40% | 50,000 | New |
| 13 | MRKR | MARKER THERAPEUTICS INC | $478,293 | 0.10% | 325,370 | Hold |
| 14 | OKUR | ONKURE THERAPEUTICS INC | $404,048 | 0.09% | 88,607 | Hold |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR